All Pharmaceutical Microbiology articles – Page 13
-
NewsFlu virus variants resistant to new antiviral drug candidate lose pathogenicity, study finds
Influenza A viruses with induced resistance to a new candidate antiviral drug were found to be impaired in cell culture and weakened in animals, a new study has found.
-
NewsAiCuris and DZIF sign Collaboration and License Option Agreement
AiCuris Anti-infective Cures AG and the German Center for Infection Research (DZIF) have announced the signing of a collaboration and license option agreement.
-
NewsMutating hepatitis viruses make drug treatment more difficult
Sofosbuvir and Ribavirin combination therapy efficiently decreased viral RNA in blood and stool in patients with chronic HEV infection, but variants that are associated with antiviral resistance emerged during treatment.
-
NewsFungus yields different pathway to the same pharmaceutically important substance
Researchers analyze a fungal biosynthetic pathway and discover a capable enzyme.
-
NewsScientists identify natural PLA2 inhibitor from marine fungus Aspergillus sp. c1
The identified marine fungus metabolite HN-001 ameliorates lipotoxicity by suppressing IRE-1α/XBP-1s axis and JNK pathway for MAFLD treatment with PLA2 as an upstream target.
-
NewsCollaborative infectious disease research takes aim at bystander cells
Researchers examining disease infection in bystander cells were granted nearly $500,000 from the Chan Zuckerberg Initiative to advance their work.
-
NewsNovo Nordisk Foundation partners with CARB-X to fight drug-resistant infections
The Novo Nordisk Foundation is committing up to $25 million to support the early-stage development of innovative tools to prevent, diagnose and treat the most dangerous drug-resistant bacterial infections. The three-year grant will go to the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), the leading global non-profit public-private partnership in this ...
-
NewsNew approach could address antibiotic resistance to Mycobacterium abscessus
Scientists have designed new versions of the drug spectinomycin that overcome efflux, the main mechanism driving resistance.
-
NewsCalibr announces license agreement with Gilead to develop long-acting HIV antiviral agent
Long-acting combination HIV regimens have the potential to transform the future of coordinated HIV clinical care
-
News Study demonstrates potency of synthetic antibiotic against serious chronic infections
A new synthetic antibiotic is shown to be more effective than established drugs against ‘superbugs’ such as MRSA, a new study shows.
-
News“Honey, I shrunk the cookbook” – new approach to vaccine development
Bioinformaticians have presented a method for identifying epitopes that promise safe immunisation across the broadest possible population group.
-
NewsResearchers use AI to identify a new class of antibiotic candidates
Using deep learning, researchers have discovered a class of compounds that can kill methicillin-resistant Staphylococcus aureus (MRSA) grown in a lab dish and in two mouse models of MRSA infection.
-
NewsAntibiotic substance isolated from bacteria in the human nose
Researchers have discovered a novel antibiotic substance from the human nose that can be used against pathogenic bacteria. Epifadin is produced from specific strains of the bacterial species Staphylococcus epidermidis.
-
NewsNanoparticles with antibacterial action shorten duration of tuberculosis treatment
A low-cost technology involving nanoparticles loaded with antibiotics and other antimicrobial compounds that can be used in multiple attacks on infections by the bacterium responsible for most cases of tuberculosis has been developed.
-
NewsResearchers reveal breakthrough in the development of drug for sleeping sickness
A novel way to attack the trypanosome parasite through its ribosome prevents the parasite from producing essential proteins, thus impairing its ability to survive.
-
NewsNew weapon against the super tough C diff bacteria shows promise
A researcher has demonstrated that a newer generation tetracycline antibiotic, Omadacycline, may be a promising tool in combating the resilient bacteria Clostridioides difficile (C diff), which causes an infection often picked up in hospitals.
-
NewsMedicinal plants offer hope for drug discovery and development against COVID-19
A new book offers insights into treating SARS-CoV-2 infections and respiratory problems, highlighting prospective drug discovery opportunities based on bioactive components from medicinal plants and herbal remedies.
-
NewsNew oral treatment reduces duration and symptoms of mild COVID-19
The treatment acts on the replication mechanism of SARS-CoV-2, the virus responsible for the disease, and reduces the severity and duration of some of the symptoms. In addition, it can be useful to treat the different mutations detected.
-
NewsDenovAI uses artificial intelligence to discover therapeutic antibodies
Kashif Sadiq has founded a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
-
NewsTeam-up of two new substances paves the way for new antibiotics
A new study shows how a combination of two new substances effectively kills methicillin-resistant Staphylococcus aureus (MRSA).